SGS ENROLLS FIRST PATIENT INTO BIOPHYTIS’ COVA CLINICAL STUDY, A COVID-19 CLINICAL TRIAL

SGS is pleased to announce the enrolment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of a potential drug candidate for people suffering with COVID-19 related respiratory failure. SGS was chosen by French biotech company Biophytis to conduct its COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. The study, which has so-far received regulatory approval in Belgium, France, Brazil, the UK, and US, will initially recruit around 50 patients who have tested positive for COVID-19 and have also developed severe respiratory symptoms in the previous seven days. They must have obvious COVID-19 symptoms – e.g. pneumonia and oxygen distress – but cannot have been reliant on high-flow oxygen use or assisted ventilation during the previous 28-days.

For more information on SGS ENROLLS FIRST PATIENT INTO BIOPHYTIS’ COVA CLINICAL STUDY, A COVID-19 CLINICAL TRIAL talk to SGS United Kingdom Ltd